In contrast, a report suggested that I-CBP112 was likely to activate CBP/EP300 in an allosteric manner through bromodomain interactions, enhancing H3K18 acetylation in acute leukemia and prostate cancer cells within a concentration range effective for its antiproliferative effects [106]. The gene discussed is CREBBP; the disease is prostate cancer.